The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Wednesday, Nov. 10, 2021

2–6 p.m. EST

2 p.m. Welcome: Unleashing Curiosity, Courage and Conviction for The Next Wave of Immunotherapy
Zhen Su, MD, MBA - Marengo Therapeutics

Session I: Immunity Beyond T cells

Time: 2:10–3:20 p.m.
Moderator: Francesco M. Marincola, MD - Kite, A Gilead Company

2:10 p.m. Beyond the Horizon. How Targeting Myeloid cells can Revolutionize Cancer Immunotherapy
Dmitry I. Gabrilovich, MD, PhD - AstraZeneca

2:30 p.m. Leveraging B-cell Immunity to Promote PD-1 blockade Effectiveness in Glioblastoma
David Hou - Northwestern University

2:40 p.m. A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence
James B. Trager, PhD - Nkarta Therapeutics

2:50 p.m. Panel Discussion
Moderator: Francesco M. Marincola, MD - Kite, A Gilead Company
Panelists: Dmitry I. Gabrilovich, MD, PhD - AstraZeneca
David Hou - Northwestern University
Katy Rezvani, MD, PhD - MD Anderson Cancer Center
James B. Trager, PhD - Nkarta Therapeutics
Session II: CAR T and other Cell Therapies in Solid Tumors

**Time:** 3:20–4:30 p.m.

**Moderator:** Kald Abdallah, MD, PhD - Bristol Myers Squibb

3:20 p.m. Equipping CAR T for Solid Tumors: Challenges and Opportunities
Carl H. June, MD - University of Pennsylvania

3:40 p.m. Secretion of Matrix Metallopeptidase 8 Promotes Tumor Infiltration and Antitumor Activity of CAR T cells
Irfan N. Bandey, PhD - University of Houston

3:50 p.m. AlloCAR TTM Cells Built for Enhanced Expansion, Persistence, and the Ability to Overcome the Solid Tumor Microenvironment
Barbra J. Sasu, PhD - Allogene Therapeutics

4:00 p.m. Debate/Panel Discussion
**Moderator:** Kald Abdallah, MD, PhD - Bristol Myers Squibb
**Panelists:** Irfan N. Bandey, PhD - University of Houston
Carl H. June, MD - University of Pennsylvania
Marcela V. Maus, MD, PhD - Massachusetts General Hospital
Barbra J. Sasu, PhD - Allogene Therapeutics

4:30 p.m. Break

Session III: Novel Combinations

**Time:** 4:45–6:00 p.m.

**Moderator:** Giovanni Melillo, MD - AstraZeneca

4:45 p.m. The Evolving Landscape of Immunotherapy Combinations
Jonathan Cheng, MD - Bristol Myers Squibb

5:05 p.m. Beyond T cells and Bispecific Antibodies for Solid Tumors: Odyssey of Bispecific Antibody (BiAb) Armed Activated T cells (BATs)
Lawrence G. Lum, MD, DSc - University of Virginia

5:15 p.m. INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma
David A. Reardon, MD - Dana-Farber Cancer Institute
5:25 p.m.  
**Panel Discussion**

**Moderator:** Giovanni Melillo, MD - AstraZeneca  
**Panelists:** Jonathan Cheng, MD - Bristol Myers Squibb  
Sandra Demaria, MD - Weill Cornell Medicine  
Lawrence G. Lum, MD, DSc - University of Virginia  
David A. Reardon, MD - Dana-Farber Cancer Institute

5:55 p.m.  
**Closing Remarks**

Kald Abdallah, MD, PhD - Bristol Myers Squibb